Santos Fernanda Maria, Marin Jose Flavio Gomes, Lima Marcos Santos, Silva-Junior Wellington Fernandes, Alves Lucas Bassolli O, Moreira Frederico R, Velasques Rodrigo Dolphini, Atanazio Marcelo Junqueira, Maia Ana Carolina Arrais, Buchpiguel Carlos A, Buccheri Valeria, Rocha Vanderson
Instituto Do Cancer Do Estado de Sao Paulo (ICESP), Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo-SP, Brazil.
Nuclear Medicine Medical Investigation Laboratory LIM43, Hospital das Clinicas, FMUSP (HCFMUSP), Sao Paulo-SP, Brazil.
Ann Hematol. 2024 Jan;103(1):175-183. doi: 10.1007/s00277-023-05461-6. Epub 2023 Oct 5.
Currently, analysis of interim PET (iPET) according to the Deauville score (DS) is the most important predictive factor in Hodgkin lymphoma (HL); however, there is room for improvement in its prognostic power. This study aimed to evaluate the prognostic value of quantitative PET analysis (maximum standard uptake value [SUV], total metabolic tumor volume [TMTV] and total lesion glicolysis [TLG]) at baseline (PET0) and iPET in a retrospective cohort of newly diagnosed classical HL. For positive iPET (+ iPET), the reduction of quantitative parameters in relation to PET0 (ΔSUV, ΔTMTV and ΔTLG) was calculated. Between 2011 and 2017, 234 patients treated with ABVD were analyzed. Median age was 30 years-old, 59% had advanced stage disease, 57% a bulky mass and 25% a + iPET (DS 4-5). At baseline, high TLG was associated with an increased cumulative incidence of failure (CIF) (p = 0.032) while neither SUV, TMTV or TLG were associated with overall survival (OS) or progression-free survival (PFS). In multivariate analysis, only iPET was associated with CIF (p < 0.001). Among ΔSUV, ΔTMTV and ΔTLG, only a ΔSUV ≥ 68.8 was significant for PFS (HR: 0.31, CI95%: 0.11-0.86, p = 0.024). A subset of patients with improved PFS amongst + iPET was identified by the quantitative (ΔSUV ≥ 68.8%) analysis. In this real-world Brazilian cohort, with prevalent high-risk patients, quantitative analysis of PET0 did not demonstrate to be prognostic, while a dynamic approach incorporating the ΔSUV to + iPET succeeded in refining a subset with better prognosis. These findings warrant validation in larger series and indicate that not all patients with + iPET might need treatment intensification.
目前,根据多维尔评分(DS)对中期PET(iPET)进行分析是霍奇金淋巴瘤(HL)最重要的预测因素;然而,其预后能力仍有提升空间。本研究旨在评估在一个新诊断的经典HL回顾性队列中,基线(PET0)和iPET时定量PET分析(最大标准摄取值[SUV]、总代谢肿瘤体积[TMTV]和总病变糖酵解[TLG])的预后价值。对于阳性iPET(+iPET),计算相对于PET0的定量参数降低值(ΔSUV、ΔTMTV和ΔTLG)。2011年至2017年期间,对234例接受ABVD治疗的患者进行了分析。中位年龄为30岁,59%患有晚期疾病,57%有大包块,25%有+iPET(DS 4 - 5)。在基线时,高TLG与失败累积发生率(CIF)增加相关(p = 0.032),而SUV、TMTV或TLG均与总生存期(OS)或无进展生存期(PFS)无关。在多变量分析中,只有iPET与CIF相关(p < 0.001)。在ΔSUV、ΔTMTV和ΔTLG中,只有ΔSUV≥68.8%对PFS有显著意义(HR:0.31,CI95%:0.11 - 0.86,p = 0.024)。通过定量(ΔSUV≥68.8%)分析在+iPET患者中识别出了一部分PFS改善的患者亚组。在这个以高危患者为主的巴西真实世界队列中,PET0的定量分析未显示出预后价值,而将ΔSUV纳入+iPET的动态方法成功地细化出了一个预后较好的亚组。这些发现需要在更大的系列中进行验证,并表明并非所有+iPET患者都需要强化治疗。